Gadolinium

Gadolinium Risks

Gadolinium is used in contrast agents for MRIs and may cause NSF. Gadolinium-based contrast agents, typically used in MRI exams, have recently been linked to a disease known as NSF or nephrogenic systemic fibrosis. This destructive disease, for which there is no known cure or treatment, causes the skin and connective tissue to thicken, affecting the ability to move, and increasing the risk of bone fractures. In a recent report issued by the FDA, it was noted that this type of contrast material is favored particularly in patients with chronic kidney disease, and can produce this serious ailment after even only a single injection of the gadolinium agents. The FDA has identified the following gadolinium agents and their respective manufacturers: gadopentetate dimeglumine or Magnevist (Bayer Schering Pharama); gadodiamide, Ominiscan (GE Healthcare); gadoversetamide or Optimark (Mallinckrodt, Inc.); gadobenate dimeglumine or MultiHance and gadoteridol, ProHance by Bracco Diagnostics Inc.

Ashkin Law Firm
580 Broadway Suite 906
New York, New York 10012
Office: 212 -965-0010
Fax: 212 -965-1301
» click here to locate our office